Schrodinger reported robust software and drug discovery revenue in the second quarter. Lilly's planned multi-billion-dollar acquisition of Morphic also provides another validation point for ...

Schrodinger's shares have declined sharply in recent weeks, due largely to soft guidance for the fourth quarter. There is little reason to believe that this is anything more than a temporary headwind ...